← Russell 3000 cross-section

AXGN Axogen, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$2.8bn
Revenue TTM
$251m
Net income TTM
$-34m
Free cash flow
$9m
Composite score
51.4
Sector rank
#1437

Valuation

P / E
EV / EBITDA
EV / sales
10.8
FCF yield
0.31%
Earnings yield vs 10-yr
-5.92pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-13.4%
EBITDA margin
-2.5%
ROE
-13.1%
ROIC
-8.9%
Revenue growth
23.6%

Insider activity, last 90 days

Net open-market
$-4.48m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Management’s Discussion and Analysis of Financial Condition and Results of Operations - Continued (in thousands, except share and per share amounts) Results of Operations Comparison of the Three Months Ended June 30, 2026 and 2025 The following table sets forth, for the periods presented, our results of operations expressed as dollar amounts and percentage of total revenue: Revenues Revenues for the three months ended June 30, 2026 increased $13,069, or 23.1%, to $69,731, as compared to $56,662 for the three months ended June 30, 2025. The increase in revenues was primarily driven by an increase in unit volume and the impact of changes in price. …Axogen, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →